TELIGENT, INC. (NASDAQ:TLGT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d)Effective September 15, 2017, the Board of Directors (the “Board”) of Teligent, Inc. (the “Company”) approved the appointment of Thomas Sabatino Jr., to serve as a member of the Board. Mr. Sabatino has also been appointed to serve as a member of the Company’s Audit Committee of the Board.
There are no arrangements or understandings between Mr. Sabatino and any other person to which Mr. Sabatino was appointed as a director. There are no transactions to which the Company is a party and in which Mr. Sabatino has a material interest that is required to be disclosed under Item 404(a) of Regulation S-K.
Mr. Sabatino will be compensated for his service on the Board in accordance with the Company’s director compensation policy and will be reimbursed for reasonable expenses incurred in connection with his service on the Board. In addition, the Company will enter into its standard form of director and officer indemnification agreement with Mr. Sabatino.
Item 8.01 Other Events.
The Company issued a press release in connection with the appointment of Mr. Sabatino to the Board. The full text of the press release is filed as Exhibit99.1 to this Current Report on Form8-K.
Item 9.01. Financial Statements and Exhibits.
Teligent, Inc. ExhibitEX-99.1 2 exhibit991pressreleasesaba.htm EXHIBIT 99.1 Exhibit Exhibit 99.1News FromBuena,…To view the full exhibit click
About TELIGENT, INC. (NASDAQ:TLGT)
Teligent, Inc., formerly IGI Laboratories, Inc., is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It has two platforms: developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. Its pipeline includes over 30 Abbreviated New Drug Applications filed with the United States Food and Drug Administration for additional pharmaceutical products. It holds additional over 40 product candidates at various stages of its development pipeline, 10 of which are on stability testing.